VeriMom¿Es myristoyl octapeptide-31 seguro durante el embarazo?
No harmonised CLP reproductive classification (ECHA Annex VI) and no SCCS/CIR safety assessment flagging reproductive hazard. Peer‑reviewed literature and public databases (PubChem, CosIng) contain no reproductive toxicity or teratogenicity data for myristoyl octapeptide‑31. As an acylated cosmetic peptide with increased lipophilicity vs the parent peptide, topical absorption is plausible but expected to be low for typical cosmetic use (hence exposure = 1). Sources consulted: ECHA Annex VI (no harmonised CLP), CosIng, PubChem, PubMed (no reproductive studies found), CIR (no assessment).
Related ingredients
Frequently asked questions
- ¿Es myristoyl octapeptide-31 seguro durante el embarazo?
- No harmonised CLP reproductive classification (ECHA Annex VI) and no SCCS/CIR safety assessment flagging reproductive hazard. Peer‑reviewed literature and public databases (PubChem, CosIng) contain no reproductive toxicity or teratogenicity data for myristoyl octapeptide‑31. As an acylated cosmetic peptide with increased lipophilicity vs the parent peptide, topical absorption is plausible but expected to be low for typical cosmetic use (hence exposure = 1). Sources consulted: ECHA Annex VI (no harmonised CLP), CosIng, PubChem, PubMed (no reproductive studies found), CIR (no assessment).
- ¿Es myristoyl octapeptide-31 seguro durante la lactancia?
- No data indicating damage to lactation or transfer into breastmilk; no harmonised classification or regulatory safety warnings. By analogy to other topical peptides and given modest dermal absorption potential, low but measurable exposure is assumed during topical use. Same data sources as for pregnancy show no reproductive/lactation concerns.
- ¿Es myristoyl octapeptide-31 seguro para la piel del bebé?
- No infant‑specific toxicology or dermal absorption studies identified. Because infant skin (0–3 yr) has higher surface‑area‑to‑bodyweight and a less mature barrier, dermal exposure was conservatively increased by one exposure level versus adults (adult e=1 → baby e=2). No evidence suggests increased inherent reproductive or mechanistic hazard to infants.
- ¿Cómo puntúa VeriMom a myristoyl octapeptide-31?
- VeriMom puntúa myristoyl octapeptide-31 en 93/100 (sin riesgos conocidos) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a myristoyl octapeptide-31 en el embarazo?
- Consulta nuestra lista de alternativas seguras a myristoyl octapeptide-31 según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.